Cvetinovic Natasa, Isakovic Andjelka M, Lainscak Mitja, Dungen Hans-Durk, Nikolic Natasa Markovic, Loncar Goran
Department of Cardiology, Zvezdara University Medical Center, Belgrade, Serbia.
School of Medicine, University of Belgrade, Serbia.
Biomark Med. 2017 Oct;11(10):893-903. doi: 10.2217/bmm-2017-0160. Epub 2017 Oct 4.
Although procalcitonin (PCT) was evaluated for the first time in the setting of heart failure (HF) in 1999, its utility in HF patients is still under examination. Patients with HF have significantly higher plasma PCT concentrations than healthy subjects and PCT levels are associated with severity of HF. It has been confirmed that higher levels of PCT are associated with worse outcomes, such as increased mortality and higher rate of rehospitalization, in HF patients with no evidence of infection. Furthermore, it has been approved that PCT-guided antibiotic treatment in HF patients reduces duration of antibiotic therapy and improves outcomes. This review summarizes current evidence from the published literature of the usefulness and limitations of PCT as a biomarker in HF.
尽管1999年就首次对降钙素原（PCT）在心力衰竭（HF）中的应用进行了评估，但其在HF患者中的效用仍在研究中。HF患者的血浆PCT浓度显著高于健康受试者，且PCT水平与HF的严重程度相关。已证实，在无感染证据的HF患者中，较高水平的PCT与更差的预后相关，如死亡率增加和再住院率升高。此外，已证实PCT指导的HF患者抗生素治疗可缩短抗生素治疗时间并改善预后。本综述总结了已发表文献中关于PCT作为HF生物标志物的有用性和局限性的现有证据。
